FEED Validator

for Atom and RSS and KML

Congratulations!

This is a valid RSS feed.

Recommendations

This feed is valid, but interoperability with the widest range of feed readers could be improved by implementing the following recommendations.

line 39, column 0: description should not contain decoding attribute (8 occurrences) [help]
```
					<description><![CDATA[<div style="margin-bottom:20px;"><img width="144" ...
```
line 40, column 0: content:encoded should not contain decoding attribute (36 occurrences) [help]
```
										<content:encoded><![CDATA[<div style="margin-bottom:20px;"><img wi ...
```
line 77, column 0: description should not contain loading attribute (7 occurrences) [help]
```
					<description><![CDATA[<div style="margin-bottom:20px;"><img width="144" ...
```
line 78, column 0: content:encoded should not contain loading attribute (16 occurrences) [help]
```
										<content:encoded><![CDATA[<div style="margin-bottom:20px;"><img wi ...
```
line 81, column 0: content:encoded should not contain data-name attribute (2 occurrences) [help]
```
<div dir="ltr" id="prni_dvprnejpg5599left" style="width: 100%; text-align: l ...
```
line 385, column 0: style attribute contains potentially dangerous content: max-height (19 occurrences) [help]
```
About MarketsandMarkets<img src="https://s.w.org/images/core/emoji/15. ...
```
line 478, column 0: content:encoded should not contain aria-invalid attribute [help]
```
Logo: <a aria-invalid="true" href="https://mma.prnewswire.com/media/25954 ...
```

Source: https://thenewsthisweek.co.uk/feed/

<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:atom="http://www.w3.org/2005/Atom"
xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
>
<channel>
<title>Rule 10b-5 Private Securities-Fraud Litigation Peaked in 4Q'24 | The News This Week</title>
<atom:link href="https://thenewsthisweek.co.uk/feed/" rel="self" type="application/rss+xml" />
<link>https://thenewsthisweek.co.uk</link>
<description></description>
<lastBuildDate>Fri, 10 Jan 2025 18:10:00 +0000</lastBuildDate>
<language>en-GB</language>
<sy:updatePeriod>
hourly </sy:updatePeriod>
<sy:updateFrequency>
1 </sy:updateFrequency>
<generator>https://wordpress.org/?v=6.7.1</generator>
<image>
<url>https://thenewsthisweek.co.uk/wp-content/uploads/2023/07/cropped-TNTW-logo-2-32x32.png</url>
<title>Rule 10b-5 Private Securities-Fraud Litigation Peaked in 4Q'24 | The News This Week</title>
<link>https://thenewsthisweek.co.uk</link>
<width>32</width>
<height>32</height>
</image>
<item>
<title>Rule 10b-5 Private Securities-Fraud Litigation Peaked in 4Q’24</title>
<link>https://thenewsthisweek.co.uk/rule-10b-5-private-securities-fraud-litigation-peaked-in-4q24-15396/</link>
<dc:creator><![CDATA[PR Newswire]]></dc:creator>
<pubDate>Fri, 10 Jan 2025 18:10:00 +0000</pubDate>
<category><![CDATA[Brand Post]]></category>
<guid isPermaLink="false">https://thenewsthisweek.co.uk/rule-10b-5-private-securities-fraud-litigation-peaked-in-4q24-15396/</guid>
<description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="82" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/01/rule-10b-5-private-securities-fraud-litigation-peaked-in-4q24.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" /></div>BETHESDA, Md., Jan. 10, 2025 /PRNewswire/ — SAR, a data analytics company specialized in the securities litigation risk of U.S. public companies, today published the Securities Class Action Rule 10b-5 Exposure Report for 4Q 2024. According to the report, securities litigation exposure of public company defendants that trade in the NYSE and NASDAQ peaked during […]]]></description>
<content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="82" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/01/rule-10b-5-private-securities-fraud-litigation-peaked-in-4q24.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" /></div>
BETHESDA, Md., Jan. 10, 2025 /PRNewswire/ — SAR, a data analytics company specialized in the securities litigation risk of U.S. public companies, today published the <a href="https://c212.net/c/link/?t=0&l=en&o=4338155-1&h=3495726593&u=https%3A%2F%2Fwww.sarlit.com%2Fsca-rule-10b-5-exposure-report&a=Securities+Class+Action+Rule+10b-5+Exposure+Report+for+4Q+2024" rel="nofollow" target="_blank">Securities Class Action Rule 10b-5 Exposure Report for 4Q 2024</a>. According to the report, securities litigation exposure of public company defendants that trade in the NYSE and NASDAQ peaked during the fourth quarter of 2024, when records were set across the buoyant U.S. equity markets. During the bullish market conditions of 2024, shareholders claimed approx. $665.2 billion in market capitalization losses due to alleged violations of Rule 10b-5 – the most in the last five years.
<div dir="ltr" id="prni_dvprnejpgb150left" style="width: 100%; text-align: left;"><img decoding="async" align="middle" alt=" " id="prnejpgb150left" src="https://mma.prnewswire.com/media/944961/SAR_Logo.jpg" title=" "></img></div>
According to the report, global quarterly Rule 10b-5 securities litigation exposure in 2024 was 17% greater than the average of 2023. Actual monetary settlements with investor plaintiffs last year were, on average, 23% greater than during the last six years.
SAR data and analysis indicate that the litigation exposure of U.S. public company defendants amounts to approximately $380.3 billion in 2H 2024. Shareholders claimed approximately $4.0 billion in market capitalization losses per securities class action filing, and approximately $2.0 billion per allegedly fraud-related stock drop in 2H 2024. The former metric increased by 32.1%, and the latter by 15.4% during the second half of 2024.
“Our data and analyses indicate that securities litigation exposure against U.S. public companies peaked in the fourth quarter of last year. This peak may be short-lived with an expected increase in volatility and new headwinds for U.S. equities given greater shareholder scrutiny of corporate disclosures. With average Rule 10b-5 settlements over 20% greater in 2024 than during the last six years, litigation activity is expected to increase in 2025,” said Anthony Kabanek, EVP of SAR.
According to the report, in 2023 and 2024 investor plaintiffs claimed $13.6 billion and $20.5 billion, respectively, in private Rule 10b-5 securities-fraud class actions that relied on short-seller research.
Key takeaways:
<ul type="disc">
<li>86 U.S. issuers were sued for alleged violations of Rule 10b-5 during 2H 2024. Based on allegations presented in the first-filed class action complaint against each defendant issuer, U.S. SCA Rule 10b-5 Exposure amounts to $259.4 billion. U.S. SCA Rule 10b-5 Exposure decreased -5.4% relative to 1H 2024. </li>
<li>U.S. SCA Rule 10b-5 Exposure peaked in the 2nd and 3rd quarters, followed by a decline to trend in the 4th quarter of 2024. </li>
<li>9 Non-U.S. issuers were sued for alleged violations of Rule 10b-5 during 2H 2024. Based on allegations presented in the first-filed class action complaint against each defendant issuer, ADR SCA Rule 10b-5 Exposure amounts to $120.9 billion. ADR SCA Rule 10b-5 Exposure increased by 11.3x relative to 1H 2024. </li>
<li>An anomalously high 4th quarter exposure among Non-U.S. issuers contributed to a remarkably volatile year for ADR SCA Rule 10b-5 Exposure. </li>
<li>Rule 10b-5 private securities-fraud filing frequency and potential loss severity need not move in tandem. Global exposure increased by approximately 34% in the 2H 2024 relative to 1H 2024, while filing frequency remained relatively stable. </li>
<li>38 U.S. Large Caps were sued for alleged violations of Rule 10b-5 in 2H 2024, the same observed frequency as 1H 2024. The U.S. Large Cap SCA Rule 10b-5 Exposure amounts to $233.7 billion, a decrease of 10.1% relative to 1H 2024. </li>
<li>22 U.S. Mid Caps were sued for alleged violations of Rule 10b-5 In 2H 2024. The U.S. Mid Cap SCA Rule 10b-5 Exposure amounts to $19.8 billion, more than 3 times the amount in 1H 2024. </li>
<li>26 U.S. Small Caps were sued for alleged violations of Rule 10b-5. The U.S. Small Cap SCA Rule 10b-5 Exposure amounts to $5.9 billion, a decrease of 33% relative to 1H 2024. </li>
<li>9 Non-U.S. issuers that trade via ADRs in the U.S. public markets were sued for alleged violations of Rule 10b-5. The ADR SCA Rule 10b-5 Exposure increased by over 11.3x to ~$121 billion, relative to 1H 2024.</li>
</ul>
Media contact: <a href="mailto:info@sarlit.com" rel="nofollow" target="_blank">info@sarlit.com</a>
Logo – <a href="https://c212.net/c/link/?t=0&l=en&o=4338155-1&h=2181420158&u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F944961%2FSAR_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F944961%2FSAR_Logo.jpg" rel="nofollow" target="_blank">https://mma.prnewswire.com/media/944961/SAR_Logo.jpg</a>
<img decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN93694&sd=2025-01-10" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/rule-10b-5-private-securities-fraud-litigation-peaked-in-4q24-302348191.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/rule-10b-5-private-securities-fraud-litigation-peaked-in-4q24-302348191.html</a>
 <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN93694&Transmission_Id=202501101310PR_NEWS_EURO_ND__EN93694&DateId=20250110" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.
]]></content:encoded>
</item>
<item>
<title>Chronic Disease Management: Innovations in Therapeutics, Devices, and Global Markets</title>
<link>https://thenewsthisweek.co.uk/chronic-disease-management-innovations-in-therapeutics-devices-and-global-markets-15398/</link>
<dc:creator><![CDATA[PR Newswire]]></dc:creator>
<pubDate>Fri, 10 Jan 2025 17:48:00 +0000</pubDate>
<category><![CDATA[Brand Post]]></category>
<guid isPermaLink="false">https://thenewsthisweek.co.uk/chronic-disease-management-innovations-in-therapeutics-devices-and-global-markets-15398/</guid>
<description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="36" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/01/chronic-disease-management-innovations-in-therapeutics-devices-and-global-markets.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>Emerging Technologies Revolutionize Chronic Disease Management: Insights into Bio-Wearables, Digital Therapeutics, and AI-Driven Solutions BOSTON, Jan. 10, 2025 /PRNewswire/ — According to the latest study from BCC Research, “Chronic Disease Management: Therapeutics, Device Technologies, and Global Markets,” is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth […]]]></description>
<content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="36" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/01/chronic-disease-management-innovations-in-therapeutics-devices-and-global-markets.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>
Emerging Technologies Revolutionize Chronic Disease Management: Insights into Bio-Wearables, Digital Therapeutics, and AI-Driven Solutions
BOSTON, Jan. 10, 2025 /PRNewswire/ — According to the latest study from BCC Research, “<a href="https://www.bccresearch.com/market-research/healthcare/chronic-disease-management-market-report.html?utm_source=PRNWHLC239C&utm_medium=referral&utm_campaign=prnewswire" rel="nofollow" target="_blank">Chronic Disease Management: Therapeutics, Device Technologies, and Global Markets</a>,” is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
<div dir="ltr" id="prni_dvprnejpg5599left" style="width: 100%; text-align: left;"><img decoding="async" align="middle" alt="BCC Research" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2183242%2FBCC_Research_Logo.jpg" id="prnejpg5599left" src="https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg" title="BCC Research"></img></div>
The report on the global market for chronic disease management spotlights trends from 2023, estimates for 2024, and projections through 2029. It evaluates the market potential for various therapeutics and advanced device technologies, covering pharmaceuticals, biologics, traditional and wearable medical devices, and digital therapeutics. The report also examines market drivers, restraints, opportunities, and the competitive landscape.
One advance in chronic disease management is biowearable technology, as exemplified by Abbott’s FreeStyle Libre. This device allows real-time tracking of biomarkers, such as glucose levels, via smartphone, reducing the frequency of clinic visits and enabling personalized, proactive care. This highlights the growing importance of digital therapeutics and wearable devices in improving patient outcomes and aligns with current market trends in chronic disease management.
The factors driving the global market for chronic disease management therapeutics and device technologies include:
Aging Population and Healthcare Demand: The aging global population increases the need for healthcare services, especially for chronic conditions such as diabetes and arthritis.
Rise in Chronic Diseases: The prevalence of chronic diseases is rising, due to poor diet, lack of exercise, and stress, particularly in urbanized developing countries.
Technological Advances: Biotechnology and medical devices, such as wearables and telehealth, improve chronic disease management and care efficiency.
Government Support: Government policies, funding, and public health campaigns support chronic disease management, ensuring safety and faster market entry for new treatments.
Request a sample copy of the report on <a href="https://www.bccresearch.com/market-research/healthcare/chronic-disease-management-market-report.html?ro=yes&utm_source=PRNWHLC239C&utm_medium=referral&utm_campaign=prnewswire" rel="nofollow" target="_blank">the global market for chronic disease management therapeutics and device technologies</a>.
Report Synopsis 
<div>
<table border="0" cellpadding="1" cellspacing="0" class="prnbcc">
<tr>
<td class="prnpr2 prnpl2 prnvab prncbts prnbrbrs prnbbbs prnbsbls" colspan="1" rowspan="1">
Report Metric
</td>
<td class="prnpr2 prnpl2 prnvab prncbts prnbrbrs prnbbbs prnsblb1" colspan="1" rowspan="1">
Details
</td>
</tr>
<tr>
<td class="prngen4" colspan="1" rowspan="1">
Base year considered
</td>
<td class="prngen5" colspan="1" rowspan="1">
2023
</td>
</tr>
<tr>
<td class="prngen4" colspan="1" rowspan="1">
Forecast period considered
</td>
<td class="prngen5" colspan="1" rowspan="1">
2024-2029
</td>
</tr>
<tr>
<td class="prngen4" colspan="1" rowspan="1">
Base year market size
</td>
<td class="prngen5" colspan="1" rowspan="1">
$675.0 billion
</td>
</tr>
<tr>
<td class="prngen4" colspan="1" rowspan="1">
Market size forecast
</td>
<td class="prngen5" colspan="1" rowspan="1">
$1.1 trillion
</td>
</tr>
<tr>
<td class="prngen4" colspan="1" rowspan="1">
Growth rate
</td>
<td class="prngen5" colspan="1" rowspan="1">
CAGR of 8.1% from 2024 to 2029
</td>
</tr>
<tr>
<td class="prngen4" colspan="1" rowspan="1">
Segments covered
</td>
<td class="prngen5" colspan="1" rowspan="1">
Product Type, Application, End User
</td>
</tr>
<tr>
<td class="prngen4" colspan="1" rowspan="1">
Regions covered
</td>
<td class="prngen5" colspan="1" rowspan="1">
North America, Europe, Asia-Pacific, and the Rest of the World (RoW)
</td>
</tr>
<tr>
<td class="prngen4" colspan="1" rowspan="1">
Countries covered
</td>
<td class="prngen5" colspan="1" rowspan="1">
United States, Canada, Mexico, Germany, France, Italy, Spain, U.K., Japan, China, India, Australia, and South Korea
</td>
</tr>
<tr>
<td class="prngen4" colspan="1" rowspan="1">
Market drivers
</td>
<td class="prngen5" colspan="1" rowspan="1">
• Aging population worldwide
• Growing prevalence of chronic diseases
• Technological advances in therapeutics and medical devices
• Government initiatives and funding
</td>
</tr>
</table>
</div>
 
Interesting Facts:
<ul type="disc">
<li>AI-driven devices such as GI Genius use machine learning to detect lesions in real-time during procedures. This helps with early disease detection, diagnosis, and personalized treatment.</li>
<li>Chronic diseases are projected to cost the global economy $47 trillion by 2030, with the U.S. alone facing a $42 trillion burden.</li>
</ul>
The report addresses the following questions:
1. What is the projected size and growth rate of the market?
<ul type="disc">
<li>The global market for chronic disease management therapeutics and device technologies was $675.0 billion in 2023. The market is expected to grow at a compound annual growth rate (CAGR) of 8.1%, reaching about $1.1 trillion by 2029.</li>
</ul>
2. What are the factors driving the growth of the market?
<ul type="disc">
<li>Increase prevalence of chronic diseases.</li>
<li>An aging population.</li>
<li>Digital therapeutics and other emerging technologies.</li>
<li>Government initiatives and funding.</li>
</ul>
3. Which segment will dominate the market in 2029?
<ul type="disc">
<li>The pharmaceutical drugs and biologics segment will dominate the market in 2029.</li>
</ul>
4. Which region has the highest share of the market?
<ul type="disc">
<li>North America holds the highest share.</li>
</ul>
Market leaders include:
ABBOTT
<ul type="disc">
<li>AMGEN INC.</li>
<li>ASTRAZENECA</li>
<li>BOSTON SCIENTIFIC CORP.</li>
<li>BRISTOL-MYERS SQUIBB CO.</li>
<li>F. HOFFMANN-LA ROCHE LTD.</li>
<li>GSK PLC.</li>
<li>JOHNSON & JOHNSON </li>
<li>MEDTRONIC</li>
<li>PFIZER INC.</li>
</ul>
Related reports include:
<a href="https://www.bccresearch.com/market-research/healthcare/medical-devices-technologies-and-global-markets.html?utm_source=PRNWHLC239C&utm_medium=referral&utm_campaign=prnewswire" rel="nofollow" target="_blank">Medical Devices: Technologies and Global Markets</a>: This report provides an overview of the medical device technology market, including market trends and projections through 2029. It covers key players, innovative technologies, market dynamics, and regional opportunities, with detailed analyses for major countries. The market is segmented by device type, end user, and region, excluding dental device technologies. Data from 2023 is used as the base year, with forecasts for 2024 and 2029.
<a href="https://www.bccresearch.com/market-research/healthcare/wearable-medical-devices.html?utm_source=PRNWHLC239C&utm_medium=referral&utm_campaign=prnewswire" rel="nofollow" target="_blank">Wearable Medical Devices: Technologies and Global Markets</a>: This report provides an overview of the global market for wearable medical devices, segmented by product, application, and sales channel. It includes market trends and projections through 2029, with 2023 as the base year. The report covers leading companies, technologies, applications, market dynamics, and regional opportunities.
Directly purchase a <a href="https://www.bccresearch.com/market-research/healthcare/chronic-disease-management-market-report.html?utm_source=PRNWHLC239C&utm_medium=referral&utm_campaign=prnewswire" rel="nofollow" target="_blank">copy of the report</a> from BCC Research.
For further information on any of these reports or to make a purchase, please contact <a href="mailto:info@bccresearch.com" rel="nofollow" target="_blank">info@bccresearch.com</a> 
About BCC Research
BCC Research market research reports provide objective, unbiased measurement, and assessment of market opportunities. Our experienced industry analysts’ goal is to help you make informed business decisions, free of noise and hype.
Contact Us Corporate HQ: 50 Milk St. Ste 16, Boston, MA 02109, USA Email: <a href="mailto:info@bccresearch.com" rel="nofollow" target="_blank">info@bccresearch.com</a>, Phone: +1 781-489-7301
For media inquiries, email <a href="mailto:press@bccresearch.com" rel="nofollow" target="_blank">press@bccresearch.com</a> or visit our <a href="https://www.bccresearch.com/media?utm_source=PRNWHLC239C&utm_medium=referral&utm_campaign=prnewswire" rel="nofollow" target="_blank">media page</a> for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying <a href="https://www.bccresearch.com/?utm_source=PRNWHLC239C&utm_medium=referral&utm_campaign=prnewswire" rel="nofollow" target="_blank">BCC Research LLC</a> as the source and publisher.
Logo: <a href="https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg" rel="nofollow" target="_blank">https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg</a>
<img loading="lazy" decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN93731&sd=2025-01-10" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/chronic-disease-management-innovations-in-therapeutics-devices-and-global-markets-302348206.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/chronic-disease-management-innovations-in-therapeutics-devices-and-global-markets-302348206.html</a>
 <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN93731&Transmission_Id=202501101248PR_NEWS_EURO_ND__EN93731&DateId=20250110" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.
]]></content:encoded>
</item>
<item>
<title>Sobi’s full year 2024 revenue higher than previous estimate</title>
<link>https://thenewsthisweek.co.uk/sobis-full-year-2024-revenue-higher-than-previous-estimate-15400/</link>
<dc:creator><![CDATA[PR Newswire]]></dc:creator>
<pubDate>Fri, 10 Jan 2025 17:45:00 +0000</pubDate>
<category><![CDATA[Brand Post]]></category>
<guid isPermaLink="false">https://thenewsthisweek.co.uk/sobis-full-year-2024-revenue-higher-than-previous-estimate-15400/</guid>
<description><![CDATA[STOCKHOLM, Jan. 10, 2025 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue for the full year 2024 was higher than previous estimate. Full-year revenue was approximately SEK 26,000 M, representing approximately 19% growth at constant exchange rate (CER) (1). Adjusted EBITA margin (1,2) was in the mid-30s per cent of revenues. […]]]></description>
<content:encoded><![CDATA[
STOCKHOLM, Jan. 10, 2025 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue for the full year 2024 was higher than previous estimate. Full-year revenue was approximately SEK 26,000 M, representing approximately 19% growth at constant exchange rate (CER) (1). Adjusted EBITA margin (1,2) was in the mid-30s per cent of revenues.
The main reasons for the increased revenue are higher sales than expected in Q4 across the Haemophilia portfolio and for Kineret.
<ul type="disc">
<li>Altuvoct: Higher than expected rate of new patients switching to Altuvoct in markets where the product has been launched, mainly Germany and Switzerland.</li>
<li>Elocta: Benefited from higher patient numbers across markets and in markets where Altuvoct is launched there were less switches than expected from Elocta. Favorable gross-to-net effects were also observed.</li>
<li>Alprolix: Higher than expected number of new patients as well as increase in on-demand treatments across Europe.</li>
<li>Kineret: Higher than expected sales driven mainly by positive gross-to-net adjustments and favorable order phasing but also supported by increased demand.</li>
<li>The adjusted EBITA margin remained in the expected range as the stronger revenue performance was offset by negative mix effects on the gross margin as well as investments into our launch and pipeline products in the fourth quarter.</li>
</ul>
At the publication of the Q3 2024 report on 24 October 2024 Sobi stated the outlook for the full year 2024 to be: Revenue was anticipated to grow by a mid-teens percentage at CER and adjusted EBITA margin was anticipated to be in the mid-30s per cent of revenue.
Sobi will announce its fourth quarter and full year 2024 report on Wednesday 5 February 2025 at 8:00 am CET.
About Sobi Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology, and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia, and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Contacts For details on how to contact the Sobi Investor Relations Team, please click <a href="https://c212.net/c/link/?t=0&l=en&o=4338182-1&h=1345449218&u=https%3A%2F%2Fwww.sobi.com%2Fen%2Finvestors&a=here" rel="nofollow" target="_blank">here</a>. For Sobi Media contacts, click <a href="https://c212.net/c/link/?t=0&l=en&o=4338182-1&h=2296011430&u=https%3A%2F%2Fwww.sobi.com%2Fen%2Fmedia&a=here" rel="nofollow" target="_blank">here</a>.
This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 18:00 CET on 10 January 2025.
Gerard Tobin Head of Investor Relations
[1] Alternative Performance Measures (APMs). [2] Excluding items affecting comparability (IAC).
This information was brought to you by Cision <a href="https://c212.net/c/link/?t=0&l=en&o=4338182-1&h=683816873&u=http%3A%2F%2Fnews.cision.com%2F&a=http%3A%2F%2Fnews.cision.com" rel="nofollow" target="_blank">http://news.cision.com</a>
<a href="https://c212.net/c/link/?t=0&l=en&o=4338182-1&h=2464973468&u=https%3A%2F%2Fnews.cision.com%2Fswedish-orphan-biovitrum-ab%2Fr%2Fsobi-s-full-year-2024-revenue-higher-than-previous-estimate%2Cc4090207&a=https%3A%2F%2Fnews.cision.com%2Fswedish-orphan-biovitrum-ab%2Fr%2Fsobi-s-full-year-2024-revenue-higher-than-previous-estimate%2Cc4090207" rel="nofollow" target="_blank">https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-s-full-year-2024-revenue-higher-than-previous-estimate,c4090207</a>
The following files are available for download:
<div>
<table border="0" cellpadding="1" cellspacing="0">
<tr>
<td class="prngen1" colspan="1" rowspan="1">
<a class="prnews_a" href="https://c212.net/c/link/?t=0&l=en&o=4338182-1&h=2592709736&u=https%3A%2F%2Fmb.cision.com%2FMain%2F14266%2F4090207%2F3201026.pdf&a=https%3A%2F%2Fmb.cision.com%2FMain%2F14266%2F4090207%2F3201026.pdf" rel="nofollow" target="_blank">https://mb.cision.com/Main/14266/4090207/3201026.pdf</a>
</td>
<td class="prngen1" colspan="1" rowspan="1">
Sobi’s full year 2024 revenue higher than previous estimate
</td>
</tr>
</table>
</div>
<img loading="lazy" decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN93716&sd=2025-01-10" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/sobis-full-year-2024-revenue-higher-than-previous-estimate-302348202.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/sobis-full-year-2024-revenue-higher-than-previous-estimate-302348202.html</a>
 <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN93716&Transmission_Id=202501101245PR_NEWS_EURO_ND__EN93716&DateId=20250110" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.
]]></content:encoded>
</item>
<item>
<title>RingConn Takes Center Stage at CES 2025 with Innovative Wearables: Gen 2 and Gen 2 Air</title>
<link>https://thenewsthisweek.co.uk/ringconn-takes-center-stage-at-ces-2025-with-innovative-wearables-gen-2-and-gen-2-air-15401/</link>
<dc:creator><![CDATA[PR Newswire]]></dc:creator>
<pubDate>Fri, 10 Jan 2025 17:00:00 +0000</pubDate>
<category><![CDATA[Brand Post]]></category>
<guid isPermaLink="false">https://thenewsthisweek.co.uk/ringconn-takes-center-stage-at-ces-2025-with-innovative-wearables-gen-2-and-gen-2-air-15401/</guid>
<description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="127" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/01/ringconn-takes-center-stage-at-ces-2025-with-innovative-wearables-gen-2-and-gen-2-air.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>LAS VEGAS, Jan. 10, 2025 /PRNewswire/ — RingConn, a leading smart wearable brand, is proud to announce its participation in this year’s CES, showcasing two groundbreaking products on the international stage: the RingConn Gen 2, which successfully raised over $4 million on Kickstarter in September, and the debut of the RingConn Gen 2 Air. Record-breaking […]]]></description>
<content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="127" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/01/ringconn-takes-center-stage-at-ces-2025-with-innovative-wearables-gen-2-and-gen-2-air.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>
LAS VEGAS, Jan. 10, 2025 /PRNewswire/ — RingConn, a leading smart wearable brand, is proud to announce its participation in this year’s CES, showcasing two groundbreaking products on the international stage: the RingConn Gen 2, which successfully raised over $4 million on Kickstarter in September, and the debut of the RingConn Gen 2 Air.
<div dir="ltr" id="prni_dvprnejpga4a7left" style="width: 100%; text-align: left;"><img decoding="async" align="middle" alt="RingConn at CES 2025" id="prnejpga4a7left" src="https://mma.prnewswire.com/media/2595273/WechatIMG49.jpg" title="RingConn at CES 2025"></img></div>
Record-breaking Launch of RingConn Gen 2
Launched in August 2024, the RingConn Gen 2 crowdfunding project achieved remarkable success as the world’s first smart ring to offer sleep apnea monitoring. With its industry-leading design, exceptional user experience, and the ultrathin hardware design, the Gen 2 garnered over $4 million in sales from more than 18,000 backers globally, setting a record for wearable brands on the platform. By the end of 2024, RingConn reached a significant milestone with over 150,000 users across 80 countries. The international debut of the Gen 2 at CES received widespread acclaim from both media and consumers.
A senior editor remarked that RingConn Gen 2 emerges as a standout smart ring at CES, offering groundbreaking sleep apnea monitoring, ultra-thin design, and comprehensive health tracking without subscription fees. Its 90.7% sleep apnea detection accuracy and 12-day battery life make it a promising innovation in wearable health technology.
Introducing AI Health Partner
Building on the success of Gen 2, the team has continuously innovated and introduced the AI Health Partner feature. This service aims to address the limitations of current AI and large language models (LLM) in health scenarios by integrating with smart wearable devices, to provide personalized, proactive, and data-driven partnering for everyday behaviors. Now, the AI Health Partner provides smart health summaries, AI-powered health goals, and intelligent health suggestions. In the long run, it should help user in providing deep Insights, Real-Time feedback, and sustainable health management, by establishing a central system that integrates user data to provide personalized health insights, AI Health Partner will conduct deeper analyses and offer recommendations.
RingConn Gen 2 Air: The Future of Smart Wearable
At CES this year, RingConn also introduced the latest addition to its product line: the RingConn Gen 2 Air. Upholding the vision of “AI Health For All – All People, All Time, All Scenarios,” this product aims to deliver cutting-edge health monitoring technology experiences to everyone. The Gen 2 Air embodies an innovative approach to smart ring design, simultaneously delivering a comprehensive health monitoring experience that builds upon the foundational capabilities of its predecessor. It offers a fresh fashion choice for the health-conscious consumers with seven different colors of ring protectors that can match unique daily outfits, sparking various style expressions. Additionally, users can enjoy nine color options for blind box finger sleeves, enhancing their smart fashion experience.
About RingConn:
Established in 2021, RingConn is a leading personal health technology company dedicated to creating innovative products and services that transform the experience of maintaining personal wellness. Guided by the principle of “Hardware + Software + Services,” RingConn aims to provide unique products and services for people’s health.
Contact: Claudia Liu PR Supervisor <a href="mailto:Claudia.L@ringconn.com" rel="nofollow" target="_blank">Claudia.L@ringconn.com</a>
Photo – <a href="https://mma.prnewswire.com/media/2595273/WechatIMG49.jpg" rel="nofollow" target="_blank">https://mma.prnewswire.com/media/2595273/WechatIMG49.jpg</a>
<img loading="lazy" decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN93424&sd=2025-01-10" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/ringconn-takes-center-stage-at-ces-2025-with-innovative-wearables-gen-2-and-gen-2-air-302347859.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/ringconn-takes-center-stage-at-ces-2025-with-innovative-wearables-gen-2-and-gen-2-air-302347859.html</a>
 <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN93424&Transmission_Id=202501101200PR_NEWS_EURO_ND__EN93424&DateId=20250110" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.
]]></content:encoded>
</item>
<item>
<title>Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology</title>
<link>https://thenewsthisweek.co.uk/menarini-group-and-insilico-medicine-enter-a-second-exclusive-global-license-agreement-for-an-ai-discovered-preclinical-asset-targeting-high-unmet-needs-in-oncology-15403/</link>
<dc:creator><![CDATA[PR Newswire]]></dc:creator>
<pubDate>Fri, 10 Jan 2025 15:45:00 +0000</pubDate>
<category><![CDATA[Brand Post]]></category>
<guid isPermaLink="false">https://thenewsthisweek.co.uk/menarini-group-and-insilico-medicine-enter-a-second-exclusive-global-license-agreement-for-an-ai-discovered-preclinical-asset-targeting-high-unmet-needs-in-oncology-15403/</guid>
<description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="43" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/01/menarini-group-and-insilico-medicine-enter-a-second-exclusive-global-license-agreement-for-an-ai-discovered-preclinical-asset-targeting-high-unmet-needs-in-oncology.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase. Under the agreement, Menarini Group will be granted global rights to develop and commercialize the […]]]></description>
<content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="43" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/01/menarini-group-and-insilico-medicine-enter-a-second-exclusive-global-license-agreement-for-an-ai-discovered-preclinical-asset-targeting-high-unmet-needs-in-oncology.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>
<ul type="disc">
<li>This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase.</li>
<li>Under the agreement, Menarini Group will be granted global rights to develop and commercialize the asset. The deal includes a $20m upfront payment, and the combined value, including all development, regulatory, and commercial milestones, is over $550 million, followed by tiered royalties.</li>
</ul>
FLORENCE, Italy and CAMBRIDGE, Mass., Jan. 10, 2025 /PRNewswire/ — The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine (“Insilico”), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.
<div dir="ltr" id="prni_dvprnejpg73b5left" style="width: 100%; text-align: left;"><img decoding="async" align="middle" alt="Menarini logo" data-name="url$https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2296569%2FMenarini_Industrie_Farmaceutiche_Riunite_Logo.jpg" id="prnejpg73b5left" src="https://mma.prnewswire.com/media/2296569/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg" title="Menarini logo"></img></div>
The asset is a highly selective and potentially best-in-class small molecule inhibitor targeting a broad range of solid tumor cancers, devel oped with the help of Chemistry42, Insilico’s generative chemistry engine, and Insilico’s drug discovery team. The asset has successfully completed preclinical development and has demonstrated broad anti-tumor activity in selected cancers.
“We are thrilled to enter our second collaboration with Insilico Medicine, a leader in the field of generative AI, for a highly selective and potentially best-in-class small molecule targeting a broad range of cancers,” said Elcin Barker Ergun, CEO of the Menarini Group. “This asset will help us enter into new areas of high unmet need, expanding the tumor areas where we can help cancer patients with ground-breaking therapies.”
“Our previous experience with Menarini Stemline proved that the company is efficient, agile, strategic, and committed to rapidly delivering the best novel therapeutic solutions to patients with cancer, maximizing the probability of success of the program,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “Menarini Stemline’s strategic visionary management is rapidly re-shaping the field of oncology, and we are very happy to take part in their quest to extend patients’ lives around the world.”
Under the terms of the agreement, Stemline will provide a $20 million upfront payment to Insilico. The combined value of the deal, including all development, regulatory, and commercial milestones, is over $550 million, followed by tiered royalties.
Prior to this collaboration, the Menarini Group and Insilico entered an exclusive licensing agreement in January 2024 for MEN2312, an innovative small molecule for breast cancer treatment and other oncology indications.
About MEN2312 
MEN2312 was designed by Insilico’s R&D team with the help of its end-to-end Pharma Generative AI platform to inhibit KAT6 and block endocrine receptor (ER) at the transcriptional level, giving it the potential to overcome resistance to endocrine therapies due to mutation or ligand-independent constitutive activation of ER. In preclinical studies, the molecule has demonstrated potent inhibition against KAT6 in multiple CDX and PDX models with good efficacy and safety.
About The Menarini Group
The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over $4.7 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini’s products are available in 140 countries worldwide. For further information, please visit menarini.com.
About Stemline Therapeutics Inc.
Stemline Therapeutics, Inc. (“Stemline”) a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline commercializes ORSERDU® (elacestrant) in the U.S. and in the E.U., an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Stemline also commercializes ELZONRIS® (tagraxofusp-erzs), a novel targeted treatment directed to CD123 for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States and Europe, which is the only approved treatment for BPDCN in the US and EU to date. Stemline also commercializes NEXPOVIO® (selinexor) in Europe, an XPO1 inhibitor for multiple myeloma. Stemline also has an extensive clinical pipeline of small molecules and biologics in various stages of development for a host of solid and hematologic cancers.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. <a href="https://www.insilico.com/" rel="nofollow" target="_blank">www.insilico.com</a>
Logo – <a href="https://mma.prnewswire.com/media/2296569/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg" rel="nofollow" target="_blank">https://mma.prnewswire.com/media/2296569/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg</a>
<img loading="lazy" decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN93575&sd=2025-01-10" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/menarini-group-and-insilico-medicine-enter-a-second-exclusive-global-license-agreement-for-an-ai-discovered-preclinical-asset-targeting-high-unmet-needs-in-oncology-302348075.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/menarini-group-and-insilico-medicine-enter-a-second-exclusive-global-license-agreement-for-an-ai-discovered-preclinical-asset-targeting-high-unmet-needs-in-oncology-302348075.html</a>
 <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN93575&Transmission_Id=202501101045PR_NEWS_EURO_ND__EN93575&DateId=20250110" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.
]]></content:encoded>
</item>
<item>
<title>Refurbished Medical Equipment Market to Hit USD 24.41 Billion by 2029 with 7.6% CAGR | MarketsandMarkets™</title>
<link>https://thenewsthisweek.co.uk/refurbished-medical-equipment-market-to-hit-usd-24-41-billion-by-2029-with-7-6-cagr-marketsandmarkets-15405/</link>
<dc:creator><![CDATA[PR Newswire]]></dc:creator>
<pubDate>Fri, 10 Jan 2025 15:30:00 +0000</pubDate>
<category><![CDATA[Brand Post]]></category>
<guid isPermaLink="false">https://thenewsthisweek.co.uk/refurbished-medical-equipment-market-to-hit-usd-24-41-billion-by-2029-with-7-6-cagr-marketsandmarkets-15405/</guid>
<description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="49" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/01/refurbished-medical-equipment-market-to-hit-usd-24-41-billion-by-2029-with-7-6-cagr-marketsandmarkets.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>DELRAY BEACH, Fla., Jan. 10, 2025 /PRNewswire/ — The global Refurbished Medical Equipment market is expected to grow to USD 24.41 Billion by 2029, up from USD 16.93 Billion in 2024, at a CAGR of 7.6% over the forecast period. Some driving the growth of the refurbished medical equipment market include the different causes such as the […]]]></description>
<content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="49" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/01/refurbished-medical-equipment-market-to-hit-usd-24-41-billion-by-2029-with-7-6-cagr-marketsandmarkets.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>
DELRAY BEACH, Fla., Jan. 10, 2025 /PRNewswire/ — The global <a href="https://www.marketsandmarkets.com/Market-Reports/refurbished-medical-devices-market-770.html?utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=refurbishedmedicaldevicesmarket" rel="nofollow" target="_blank">Refurbished Medical Equipment market</a> is expected to grow to USD 24.41 Billion by 2029, up from USD 16.93 Billion in 2024, at a CAGR of 7.6% over the forecast period. Some driving the growth of the refurbished medical equipment market include the different causes such as the increased demand for affordable healthcare, shortage of newly procured medical devices, particularly in low-income areas, demand for affordable and high-quality refurbished equipment that bridge the gap. This has enhanced the funding support offered by the government.
<div dir="ltr" id="prni_dvprnejpg9a0bleft" style="width: 100%; text-align: left;"><img decoding="async" align="middle" alt="MarketsandMarkets Logo" id="prnejpg9a0bleft" src="https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg" style="width: 400px; height: 137px;" title="MarketsandMarkets Logo"></img></div>
Download PDF Brochure: <a href="https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=770&utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=refurbishedmedicaldevicesmarket" rel="nofollow" target="_blank">https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=770</a>
Browse in-depth TOC on “Refurbished Medical Equipment Market“ 400 – Tables 250 – Figures 420 – Pages
Notably, the refurbished medical devices have an advantage in terms of cost efficiency, so hospitals can manage their budgets much better, particularly in poorly funded healthcare systems or Enhanced Software Integration. The new-age refurbishment, with new components, makes the medical devices more durable. For example, refurbished ventilators are made from durable parts that extend their years of usage: Avante Health Solutions refurbishes their ventilators with durable parts. There are improved Regulatory Compliance, for instance, refurbished medical devices by Siemens and Philips already meet the requirements set forth by the FDA, as well as the EU MDR standards. Some updated safety features among refurbished equipment include advanced alarms and monitoring systems, along with user interfaces like some systems from Soma Tech and Meridian Medical that come with upgraded safety protocols for Refurbished patient monitors. These advances, coupled with changes on the regulatory front which simplify the pathway of refurbished products approvals.
Based on the product segment, the Refurbished medical equipment market is segmented into – medical imaging equipment, operating room & surgical equipment, patient monitors, cardiology equipment, urology equipment, neurology equipment, intensive care equipment, endoscopy equipment, intravenous therapy systems, and other medical equipment. Among them, medical imaging equipment account for the largest share in the Refurbished medical equipment market. This is possible as refurbished medical imaging machines save cost as compared to newly purchased models and allow hospitals and clinics to strengthen their practices in an advanced diagnostic setting economically. The need for imaging procedures across specialties, including but not limited to cardiology and oncology, has kept the market for quite steady refurbished equipment alive. Such equipment has permitted those healthcare systems in developing countries to improve their infrastructure without incurring the high upfront costs of new machines.
On the basis of application, the Refurbished medical equipment market is divided into diagnostic applications, therapeutic applications, and other applications. The diagnostic application segment holds the largest share of the market in 2023 as modern refurbished diagnostics are able to perform like brand-new diagnostics with the latest introduction of technology. This includes MRI systems, among many others, that use modern imaging techniques and software. Refurbished equipment helps address the growing need in affordable diagnostic devices as the healthcare infrastructure develops in emerging countries without compromising quality. The hospital can perform high-level diagnostic imaging procedures now, at a fraction of the cost of entirely new equipment, thereby improving diagnosis and care for patients while remaining budget-wise. Refurbished medical supplies are gaining greater acceptance in various parts of the world as regulatory agencies embrace their use. The FDA, for instance, has laid down specific regulations regarding the use and marketing of refurbished medical equipment.
Request Sample Pages: <a href="https://www.marketsandmarkets.com/requestsampleNew.asp?id=770&utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=refurbishedmedicaldevicesmarket" rel="nofollow" target="_blank">https://www.marketsandmarkets.com/requestsampleNew.asp?id=770</a>
Prominent players in the Refurbished medical equipment market include GE Healthcare (United States), Philips Healthcare (Netherlands), Siemens Healthineers (Germany), Block Imaging International,Inc. (US), Soma Technology, Inc. (US), Avante Health Solutions (US), and Canon Medical Systems Corp. (Japan), Mindray Medical International (China), Dragerwerk AG & Co. KGAA (Germany), Whittemore Enterprises (U.S.), Stryker (US), Directmed Parts & Services (US), Medline Industries (U.S.), Traco Medical (U.S.), and Nihon Kohden Corporation (Japan).
These players have a wide range of products and also hold a strong global presence across North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Key players in the market for Refurbished medical equipment address a strategic priority in numerous ways to grow in this market. The first involves research and development expenditure to offer newest technology in refurbished products such as integration with AI in refurbished imaging systems. Second, waste reduction and contingently minimizing all the environmental impact caused due to manufacturing new devices is aligned with a favouring trend, thus propelling growth in this market. These companies provide innovative products and services globally. They concentrate on acquisitions, partnerships and collaborations to expand their market share.
GE Healthcare (US): The refurbished medical equipment by GE Healthcare are all part of the total healthcare solutions that intend to offer cost-efficiency to healthcare providers without compromising quality. It may be helpful to mention the major drivers in the refurbished equipment market, which include improvement in diagnostic imaging and therapeutic equipment- oncology and cardiology among them- as well as increasing global affordability for reliable equipment in the healthcare setting. The refurbishment of such equipment is part and parcel of developing the larger agenda of precision health and digital transformation in healthcare. Refurbished products such as Optima CT660 go through an intense process ranging from very extensive inspection and testing. Such refurbished devices continue serving clinical settings, thus avoiding the need for fresh appliances, thereby cutting down waste.
Philips Healthcare (Netherlands): Philips Healthcare has made a major breakthrough in focusing on the refurbishment of quality, sustainable systems-mainly medical equipment-as a result of its “Circular Edition” processes. The systems have introduced totally new-their own brands of MRI, CT, Ultrasound, and Mobile C-arms-to give high-performance imaging at a cost reduced by about 25% from that for wholly new systems. Thus, healthcare facilities will have the opportunity to acquire premium high-technology equipment with high savings in total cost of ownership, while still offering these facilities every advantage that comes with such technology. Their refurbished systems go through seven rigorous steps to ensure that they meet the same standard as new ones. These include replacing faulty parts with original Philips components and making the latest software upgrades.
Siemens Healthineers (Germany): Siemens Healthineers frequents the lead in refurbished medical equipment, which has witnessed tremendous growth due to cost-containment pressures and a surge in demand for high-quality equipment in newer markets. Siemens has continued to add refurbished medical devices under diverse business segments such as medical imaging and patient monitoring equipment. The company thrives on making high quality, low-cost equipment available especially for hospitals and health care providers in North America which has increased the usage of refurbished devices owing to the extremely high costs of healthcare. In addition, the company is increasing its footprints in regions like APAC and Latin America where refurbished devices can serve as economical alternatives. Expectedly, Siemens Healthineers is a successful company into the refurbished space owing to its brand as well as all the cost benefits that accrue from refurbishing equipment while being at the same performance horizons.
For more information, <a href="https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=770&utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=refurbishedmedicaldevicesmarket" rel="nofollow" target="_blank">Inquire Now!</a>
Related Reports:
<a href="https://www.marketsandmarkets.com/Market-Reports/magnetic-resonance-imaging-market-99.html?utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=refurbishedmedicaldevicesmarket" rel="nofollow" target="_blank">MRI Systems Market</a>
<a href="https://www.marketsandmarkets.com/Market-Reports/cardiac-monitoring-advanced-technologies-and-global-market-55.html?utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=refurbishedmedicaldevicesmarket" rel="nofollow" target="_blank">Cardiac Monitoring & Cardiac Rhythm Management Devices Market</a>
<a href="https://www.marketsandmarkets.com/Market-Reports/diagnostic-imaging-market-411.html?utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=refurbishedmedicaldevicesmarket" rel="nofollow" target="_blank">Diagnostic Imaging Market</a>
<a href="https://www.marketsandmarkets.com/Market-Reports/patient-healthcare-monitoring-systems-devices-market-678.html?utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=refurbishedmedicaldevicesmarket" rel="nofollow" target="_blank">Patient Monitoring Devices Market</a>
<a href="https://www.marketsandmarkets.com/Market-Reports/minimally-invasive-surgical-instruments-devices-market-682.html?utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=refurbishedmedicaldevicesmarket" rel="nofollow" target="_blank">Minimally Invasive Surgical Instruments Market</a>
Get access to the latest updates on <a href="https://www.marketsandmarkets.com/ResearchInsight/refurbished-medical-devices-market.asp" rel="nofollow" target="_blank">Refurbished Medical Equipment Companies</a> and <a href="https://www.marketsandmarkets.com/PressReleases/refurbished-medical-devices.asp" rel="nofollow" target="_blank">Refurbished Medical Equipment Market Size</a>
About MarketsandMarkets<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" />:
MarketsandMarkets<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit <a href="http://www.marketsandmarkets.com/" rel="nofollow" target="_blank">www.MarketsandMarkets<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" />.com</a> or follow us on <a href="https://twitter.com/marketsmarkets" rel="nofollow" target="_blank">Twitter</a>, <a href="https://www.linkedin.com/company/marketsandmarkets/about/" rel="nofollow" target="_blank">LinkedIn</a> and <a href="https://www.facebook.com/MarketsandMarkets" rel="nofollow" target="_blank">Facebook</a>.
Contact: Mr. Rohan Salgarkar MarketsandMarkets<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: <a href="mailto:sales@marketsandmarkets.com" rel="nofollow" target="_blank">sales@marketsandmarkets.com</a> Visit Our Website: <a href="https://www.marketsandmarkets.com/" rel="nofollow" target="_blank">https://www.marketsandmarkets.com/</a>
Logo: <a href="https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg" rel="nofollow" target="_blank">https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg</a>
 
<img loading="lazy" decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN93443&sd=2025-01-10" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/refurbished-medical-equipment-market-to-hit-usd-24-41-billion-by-2029-with-7-6-cagr--marketsandmarkets-302347806.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/refurbished-medical-equipment-market-to-hit-usd-24-41-billion-by-2029-with-7-6-cagr–marketsandmarkets-302347806.html</a>
 <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN93443&Transmission_Id=202501101030PR_NEWS_EURO_ND__EN93443&DateId=20250110" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.
]]></content:encoded>
</item>
<item>
<title>Future of Robotics to 2030 Market and Beyond – Exclusive Report by MarketsandMarkets™</title>
<link>https://thenewsthisweek.co.uk/future-of-robotics-to-2030-market-and-beyond-exclusive-report-by-marketsandmarkets-15407/</link>
<dc:creator><![CDATA[PR Newswire]]></dc:creator>
<pubDate>Fri, 10 Jan 2025 15:15:00 +0000</pubDate>
<category><![CDATA[Brand Post]]></category>
<guid isPermaLink="false">https://thenewsthisweek.co.uk/future-of-robotics-to-2030-market-and-beyond-exclusive-report-by-marketsandmarkets-15407/</guid>
<description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="49" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/01/future-of-robotics-to-2030-market-and-beyond-exclusive-report-by-marketsandmarkets.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>DELRAY BEACH, Fla., Jan. 10, 2025 /PRNewswire/ — The report “Future of Robotics – Cobots, Humanoid & Soft Robots, Swarm Robotics, by Technology (Artificial Intelligence, Digital Twin, AR/VR, Cloud Computing), Industry (Automotive, Smart Cities, Space Exploration, Logistics, Agriculture) – Global Forecast to 2030 according to a new report by MarketsandMarkets™”. The robotics industry is rapidly […]]]></description>
<content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="49" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/01/future-of-robotics-to-2030-market-and-beyond-exclusive-report-by-marketsandmarkets.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>
DELRAY BEACH, Fla., Jan. 10, 2025 /PRNewswire/ — The report “<a href="https://www.marketsandmarkets.com/Market-Reports/future-robotics-56928872.html?utm_source=prnewswire.com&utm_medium=referral&utm_campaign=futurerobotics" rel="nofollow" target="_blank">Future of Robotics</a> – Cobots, Humanoid & Soft Robots, Swarm Robotics, by Technology (Artificial Intelligence, Digital Twin, AR/VR, Cloud Computing), Industry (Automotive, Smart Cities, Space Exploration, Logistics, Agriculture) – Global Forecast to 2030 according to a new report by MarketsandMarkets<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" />”. The robotics industry is rapidly evolving, driven by technological advancements and market demands. With AI, machine learning, and IoT integration, robots are becoming more autonomous, intelligent, and interconnected. Key trends like human-robot collaboration, advanced automation, and enhanced adaptability will shape the future of robotics, transforming industries and driving efficiency.
<div dir="ltr" id="prni_dvprnejpg9a42left" style="width: 100%; text-align: left;"><img decoding="async" align="middle" alt="MarketsandMarkets" id="prnejpg9a42left" src="https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg" title="MarketsandMarkets"></img></div>
Download PDF Brochure: <a href="https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=56928872&utm_source=prnewswire.com&utm_medium=referral&utm_campaign=futurerobotics" rel="nofollow" target="_blank">https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=56928872</a>
Browse in-depth TOC on “Future of Robotics” 
50- Tables 05 – Figures 60 – Pages
The rise of collaborative robots and their role in transforming the future of robotics
Collaborative robots are revolutionizing robotics by enabling humans and machines to work together seamlessly. Unlike traditional robots that operate in isolation, cobots are designed to collaborate with human workers, improving efficiency and safety across industries. By automating repetitive, dangerous, or physically demanding tasks, cobots free up human workers to focus on higher-value, strategic roles. Recent advancements in AI, machine learning, and sensors have made cobots smarter and more adaptable, allowing them to learn tasks, adjust to new environments, and interact with other machines in real-time. Their flexibility to be quickly reprogrammed for different tasks makes them ideal for dynamic production environments. Equipped with safety features like collision detection and force sensing, cobots work safely alongside humans, fostering safer and more productive workplaces. As key enablers of Industry 4.0, cobots are fully integrated with the Industrial Internet of Things (IIoT), optimizing workflows and enabling data-driven decision-making. Looking beyond 2030, cobots will become even more autonomous, powered by next-gen technologies like 5G and augmented reality, transforming industries and creating human-centric workplaces that drive innovation and productivity.
AI’s Revolutionary Influence on Robotics and Its Future Implications
AI is transforming robotics by making systems smarter, more adaptive, and autonomous. It empowers robots to process real-time data, make independent decisions, and optimize workflows, boosting efficiency and reducing errors. AI-driven computer vision enables robots to recognize objects, understand their surroundings, and adjust to dynamic conditions, making them ideal for precision tasks. In manufacturing, robots perform assembly and inspection with unmatched accuracy, while in logistics, they streamline warehouse operations. In healthcare, AI-powered robots assist in surgeries and patient care, ensuring high precision and safety. Collaborative robots (cobots) benefit from AI by interacting safely with humans, adapting to their actions, and ensuring smooth cooperation. AI also advances predictive maintenance, allowing robots to monitor their own performance, detect potential issues, and schedule maintenance to minimize downtime. Additionally, AI enables robots to learn and adapt to specific tasks through machine learning, enhancing flexibility. By embedding intelligence into automation, AI is driving innovation across industries like automotive, aerospace, electronics, and agriculture, creating systems that can handle complex tasks and optimize operations. In the coming years, AI will continue to shape the future of robotics by enabling even more autonomous, intelligent systems that will redefine industries, streamline processes, and create new opportunities for human-robot collaboration, pushing the boundaries of innovation and operational efficiency.
The Impact of AR and VR on Robotics’ Future Development
Augmented Reality (AR) and Virtual Reality (VR) are revolutionizing robotics by enhancing design, training, and operational efficiency. AR improves human-robot interaction by overlaying digital information onto real-world environments, allowing for better visualization of robotic systems and optimized workflows. For example, ABB Robotics uses AR to simulate robotic systems before physical construction, reducing costs and development time. In training, VR offers immersive environments where operators can practice without risk, while AR provides real-time guidance during complex tasks. This combination is especially beneficial in hazardous jobs, where VR-controlled robots enable remote operation for enhanced safety. Furthermore, the integration of AR with Artificial Intelligence (AI) enhances robot performance through intuitive controls and feedback, facilitating advanced applications like robot-assisted surgery and navigation. The synergy of AR, VR, and robotics promises to drive significant advancements across industries like healthcare, manufacturing, automotive, aerospace, and logistics, shaping the future of robotics in the years to come.
Humanoid Robots Are Pioneering a New Era in Human-Machine Collaboration.
Humanoid robots are advanced machines designed to replicate human form and behavior, enabling them to perform tasks alongside humans in industries like manufacturing, healthcare, logistics, and retail. Powered by cutting-edge technologies such as AI, mechatronics, and advanced sensors, these robots are engineered to operate in dynamic environments like factories, warehouses, and hospitals. Companies like Tesla, Boston Dynamics, and Agility Robotics are leading the way, investing heavily in AI-powered robots that are becoming increasingly capable and versatile. Tesla has already integrated its Optimus robots into its factory operations, with plans for wider deployment, while Agility Robotics is building a factory in Oregon to produce 10,000 robots annually. The US and China are at the forefront of this revolution, driven by significant investments and rapid technological advancements. Humanoid robots will transform industrial operations as they evolve to become more intelligent, adaptable, and cost-effective. Over the coming years, they will seamlessly integrate into human environments, improving efficiency, safety, and quality of life across sectors, marking the beginning of a new era in robotics.
Swarm robotics will shape the future of automation and efficiency
Swarm robotics is an emerging field inspired by the collective behavior of social insects like ants, birds, and bees. It involves coordinating simple, autonomous robots that work together to accomplish complex tasks. Unlike traditional robots, which are often centrally controlled and sophisticated, swarm robots operate through decentralized control. Each robot makes decisions based on local information, and through simple rules and interactions, the swarm exhibits emergent behavior that allows it to adapt and complete large-scale tasks. This approach offers advantages such as scalability, resilience, and flexibility, making swarm robotics ideal for applications like search and rescue, environmental monitoring, manufacturing, agriculture, and space exploration. The ability of swarm robots to function autonomously and collaborate without central control enables them to operate in challenging environments, such as disaster zones or distant planets. As technology advances, swarm robotics will play a pivotal role in shaping the future of robotics, offering innovative solutions that enhance automation, efficiency, and adaptability across various industries in the coming years.
Inquiry Before Buying: <a href="https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=56928872&utm_source=prnewswire.com&utm_medium=referral&utm_campaign=futurerobotics" rel="nofollow" target="_blank">https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=56928872</a>
Asia-Pacific region is leading the way in robotics innovation
The future of robotics in the Asia-Pacific region is set for significant transformation, driven by rapid industrialization, technological innovation, and strong government support. China’s “Made in China 2025″ initiative is advancing robotics in manufacturing and healthcare, focusing on automation to boost efficiency and reduce labor costs. Japan’s “Society 5.0” strategy is integrating AI and robotics into daily life, particularly in automotive and electronics, with companies like Fanuc and Yaskawa leading in collaborative robots. India is emerging as a key player in service robotics, with a growing number of startups focused on healthcare and domestic automation solutions. The Indian government is supporting this growth through schemes like the “Production Linked Incentive” (PLI) scheme and “Startup India,” encouraging innovation and research in robotics. Additionally, initiatives like “Atmanirbhar Bharat” aim to promote self-reliance in technology, fostering the development of affordable, scalable robotic solutions. South Korea’s Smart Factory initiative is modernizing manufacturing through AI, while also advancing medical robotics. These nations are collectively reshaping industries, positioning the Asia-Pacific region as a global leader in robotics in the next 5-10 years.
Get 10% Free Customization on this Report: <a href="https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=56928872&utm_source=prnewswire.com&utm_medium=referral&utm_campaign=futurerobotics" rel="nofollow" target="_blank">https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=56928872</a>
About MarketsandMarkets<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" />
MarketsandMarkets<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit <a href="https://www.marketsandmarkets.com/" rel="nofollow" target="_blank">www.MarketsandMarkets<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" />.com</a> or follow us on <a href="https://twitter.com/marketsmarkets" rel="nofollow" target="_blank">Twitter</a>, <a href="https://www.linkedin.com/company/marketsandmarkets/about/" rel="nofollow" target="_blank">LinkedIn</a> and <a href="https://www.facebook.com/MarketsandMarkets" rel="nofollow" target="_blank">Facebook</a>.
Contact: Mr. Rohan Salgarkar MarketsandMarkets<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: <a href="mailto:sales@marketsandmarkets.com" rel="nofollow" target="_blank">sales@marketsandmarkets.com</a> Visit Our Web Site: <a href="https://www.marketsandmarkets.com/" rel="nofollow" target="_blank">https://www.marketsandmarkets.com/</a> Research Insight: <a href="https://www.marketsandmarkets.com/ResearchInsight/future-robotics.asp?utm_source=prnewswire.com&utm_medium=Referal&utm_id=futurerobotics" rel="nofollow" target="_blank">https://www.marketsandmarkets.com/ResearchInsight/future-robotics.asp</a> Content Source: <a href="https://www.marketsandmarkets.com/PressReleases/future-robotics.asp" rel="nofollow" target="_blank">https://www.marketsandmarkets.com/PressReleases/future-robotics.asp</a>
Logo: <a href="https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg" rel="nofollow" target="_blank">https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg</a>
<img loading="lazy" decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN93430&sd=2025-01-10" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/future-of-robotics-to-2030-market-and-beyond---exclusive-report-by-marketsandmarkets-302347781.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/future-of-robotics-to-2030-market-and-beyond—exclusive-report-by-marketsandmarkets-302347781.html</a>
 <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN93430&Transmission_Id=202501101015PR_NEWS_EURO_ND__EN93430&DateId=20250110" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.
]]></content:encoded>
</item>
<item>
<title>LGC Board appoints Joydeep Goswami as President & Chief Executive</title>
<link>https://thenewsthisweek.co.uk/lgc-board-appoints-joydeep-goswami-as-president-chief-executive-15384/</link>
<dc:creator><![CDATA[PR Newswire]]></dc:creator>
<pubDate>Fri, 10 Jan 2025 12:00:00 +0000</pubDate>
<category><![CDATA[Brand Post]]></category>
<guid isPermaLink="false">https://thenewsthisweek.co.uk/lgc-board-appoints-joydeep-goswami-as-president-chief-executive-15384/</guid>
<description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="143" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/01/lgc-board-appoints-joydeep-goswami-as-president-chief-executive.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>LONDON, Jan. 10, 2025 /PRNewswire/ — LGC has announced that Joydeep Goswami is joining its Board of Directors and Executive Leadership Team (ELT) as President and Chief Executive Officer (CEO). Joydeep succeeds Euan O’Sullivan, who decided to step down from his role in early 2024 after fourteen years of outstanding and dedicated service. Euan has […]]]></description>
<content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="143" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/01/lgc-board-appoints-joydeep-goswami-as-president-chief-executive.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>
LONDON, Jan. 10, 2025 /PRNewswire/ — LGC has announced that Joydeep Goswami is joining its Board of Directors and Executive Leadership Team (ELT) as President and Chief Executive Officer (CEO). Joydeep succeeds Euan O’Sullivan, who decided to step down from his role in early 2024 after fourteen years of outstanding and dedicated service. Euan has worked closely with the LGC Board since then on the appointment of his successor and will be available in an advisory capacity to Joydeep until March 2025.
<div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
 <a href="https://mma.prnewswire.com/media/2595470/LGC_Logo.html" rel="nofollow" target="_blank"> <img decoding="async" alt="LGC Logo" src="https://mma.prnewswire.com/media/2595470/LGC_Logo.jpg" title="LGC Logo"></img> </a> 
</div>
David King, Non-Executive Chairman of LGC, said: “On behalf of our Board and ELT, we are delighted to welcome Joydeep to LGC. He brings broad international experience in senior leadership roles in life sciences, focused on business transformation. He brings a strong commitment to LGC’s purpose and values, as well as a track record of driving business performance serving customers, colleagues, and shareholders.”
David added: “On behalf of our Board, ELT and colleagues, we would also like to take this opportunity to thank Euan for his exceptional contribution to LGC. Prior to taking on Group-wide leadership responsibility in the summer of 2020, Euan led the expansion of LGC’s Quality Assurance activities in the 2010s, substantially expanding our Standards business and establishing a leading presence in the clinical diagnostics and food supply chain assurance markets. As President and CEO, he has led LGC with distinction during the COVID-19 pandemic and through the subsequent necessary period of post-pandemic restructuring and renewal, against the backdrop of challenging macro-economic and geopolitical conditions. He leaves us with a tremendous platform to grow from, with the business performing well, a strong leadership team and a transformational investment programme substantially complete. We wish him every success for the future.”
In response to his appointment, Joydeep Goswami said: “LGC is a leading global life sciences tools company that is driven by its purpose – Science for a Safer World. I am pleased to be joining the company at this exciting time, particularly as key strategic capital investment projects reach completion. I look forward to being part of a customer centric company which plays a key role in driving science and innovation forward, partnering with customers to help diagnose, treat, feed and protect the growing global population.”
With over twenty-five years of global experience, Joydeep has a deep background in life sciences tools and a strong track record of developing strategy and leading new product development, partnerships, licensing, and mergers and acquisitions. His experiences as a P&L leader and CFO gives him the ability to bring customer, employee and investor perspectives to setting the strategy and allocating resources to drive strong profitable growth. 
Most recently, Joydeep served as Chief Financial Officer and Chief Strategy and Corporate Development Officer at Illumina. Prior to Illumina, Joydeep held a variety of global and business unit leadership roles with Thermo Fisher Scientific over sixteen years, culminating in his leadership of Thermo Fisher’s Clinical Next Generation Sequencing and Oncology Division. Joydeep also serves on the Board of Biolife Solutions.
Joydeep has an M.S., Ph.D. in Chemical Engineering, an MBA from the Massachusetts Institute of Technology and a bachelor’s degree in chemical engineering from the Indian Institute of Technology, Mumbai. 
About LGC
LGC is a global leader in life science tools, dedicated to partnering with customers to deliver solutions that diagnose, treat, feed, and protect our growing population. With over 180 years of scientific heritage, we collaborate with the scientific community to tackle some of the world’s most complex challenges, responding to global health crises, pioneering precision medicine, and enhancing the safety of food, medicines, and the environment.
Operating in 14 countries, LGC’s products and services are integral to industries that safeguard public health, food, water, and medicine. Our solutions help our diverse customer base—from pharmaceutical companies and diagnostic manufacturers to testing laboratories and food producers—maintain the highest standards of quality, safety, and compliance.
Together with our partners, we work toward a safer, healthier, and more sustainable world, advancing the science that protects people and the planet. For further information visit: <a href="https://www.lgcgroup.com/" rel="nofollow" target="_blank">www.lgcgroup.com</a>
Media contacts:
Edel McCaffrey, Head of Corporate Communications, LGC Group <a href="mailto:edel.mccaffrey@lgcgroup.com" rel="nofollow" target="_blank">edel.mccaffrey@lgcgroup.com</a> +44 7587 315 615
Magda Bartoszewicz, Director, Corporate Communications, LGC Group <a href="mailto:magda.barto@lgcgroup.com" rel="nofollow" target="_blank">magda.barto@lgcgroup.com</a> +44 7522 141 822|
Andrew Thomas, LGC Group Corporate Communications <a href="mailto:andrew.thomas@lgcgroup.com" rel="nofollow" target="_blank">andrew.thomas@lgcgroup.com</a> +44 7803 585 254
 
Logo: <a aria-invalid="true" href="https://mma.prnewswire.com/media/2595470/LGC_Logo.jpg" rel="nofollow" target="_blank">https://mma.prnewswire.com/media/2595470/LGC_Logo.jpg</a>
<img loading="lazy" decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN93523&sd=2025-01-10" title="Cision" width="12"></img> View original content to download multimedia:<a href="https://www.prnewswire.co.uk/news-releases/lgc-board-appoints-joydeep-goswami-as-president--chief-executive-302347913.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/lgc-board-appoints-joydeep-goswami-as-president–chief-executive-302347913.html</a>
 <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN93523&Transmission_Id=202501100700PR_NEWS_EURO_ND__EN93523&DateId=20250110" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.
]]></content:encoded>
</item>
<item>
<title>Emulsifiers Market worth $8.19 billion by 2029 – Exclusive Report by MarketsandMarkets™</title>
<link>https://thenewsthisweek.co.uk/emulsifiers-market-worth-8-19-billion-by-2029-exclusive-report-by-marketsandmarkets-15386/</link>
<dc:creator><![CDATA[PR Newswire]]></dc:creator>
<pubDate>Fri, 10 Jan 2025 11:45:00 +0000</pubDate>
<category><![CDATA[Brand Post]]></category>
<guid isPermaLink="false">https://thenewsthisweek.co.uk/emulsifiers-market-worth-8-19-billion-by-2029-exclusive-report-by-marketsandmarkets-15386/</guid>
<description><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="49" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/01/emulsifiers-market-worth-8-19-billion-by-2029-exclusive-report-by-marketsandmarkets.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>DELRAY BEACH, Fla., Jan. 10, 2025 /PRNewswire/ — The report “Emulsifiers Market by Source (Bio-based, Synthetic), Product (Lecithin, Ionic, Chemical Composition, Physical State), Application (Food, Cosmetics & Personal Care, Oilfield Chemicals, Pharmaceutical, Agrochemicals), and Region – Global Forecast to 2029″, emulsifiers market is projected to reach USD 8.19 billion by 2029 from USD 6.08 billion in 2024, at […]]]></description>
<content:encoded><![CDATA[<div style="margin-bottom:20px;"><img width="144" height="49" src="https://thenewsthisweek.co.uk/wp-content/uploads/2025/01/emulsifiers-market-worth-8-19-billion-by-2029-exclusive-report-by-marketsandmarkets.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" /></div>
DELRAY BEACH, Fla., Jan. 10, 2025 /PRNewswire/ — The report “<a href="https://www.marketsandmarkets.com/Market-Reports/emulsifier-market-240653061.html?utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=emulsifiersmarket" rel="nofollow" target="_blank">Emulsifiers Market</a> by Source (Bio-based, Synthetic), Product (Lecithin, Ionic, Chemical Composition, Physical State), Application (Food, Cosmetics & Personal Care, Oilfield Chemicals, Pharmaceutical, Agrochemicals), and Region – Global Forecast to 2029″, emulsifiers market is projected to reach USD 8.19 billion by 2029 from USD 6.08 billion in 2024, at a CAGR of 6.3% during the forecast period. The emulsifier market has been witnessing sound growth because of its massive consumption in various industries like food and beverages, cosmetics, pharmaceuticals, and industrial products. The demand for processed and ready-to-eat foodstuff, especially low-fat and low-calorie products, is leading to a high growth trend in the emulsifiers market. Emulsifiers are incorporated as they improve texture, stability, and shelf life in most present-day food processing. The cosmetics and personal care industry, where emulsifiers play an important role in stabilizing creams, lotions, and other skincare and haircare product formulations, is the biggest driver of growth. Other pharmaceutical applications, such as new drug delivery systems, are also broadening the scope of the market. Significant industrial uses include paints, coatings, and detergents, which also contribute greatly to the expansion of this market. Growth in developing economies, mainly Asia Pacific and South America, is more and more stimulated by urbanization, growing disposable incomes, as well as the trend change in consumer preference.
<div dir="ltr" id="prni_dvprnejpg151aleft" style="width: 100%; text-align: left;"><img decoding="async" align="middle" alt="MarketsandMarkets Logo" id="prnejpg151aleft" src="https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg" title="MarketsandMarkets Logo"></img></div>
Browse in-depth TOC on “Emulsifiers Market”.
262 – Tables 56 – Figures 285 – Pages
Download PDF Brochure: <a href="https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=240653061&utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=emulsifiersmarket" rel="nofollow" target="_blank">https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=240653061</a>
Synthetic emulsifier is projected to have the largest market share in 2024
Synthetic emulsifiers are expected to maintain the largest market share in the emulsifiers market because of their cost-effectiveness, versatility, and widespread applicability across industries. They offer excellent functional properties, including high emulsifying efficiency, stability under extreme conditions such as varying temperatures and pH levels, and extended shelf life, making them highly suitable for large-scale industrial applications. Synthetic emulsifiers such as mono- and diglycerides, polysorbates, and lecithin derivatives have become a staple in the food industry to improve texture, stabilize emulsions, and extend shelf life due to the growing demand for processed and convenience foods. This is further expanded into industrial use, including paints, coatings, lubricants, and detergents, where superior stability and performance under extreme conditions are important. Synthetic emulsifiers also have well-established supply chains and manufacturing infrastructure, ensuring consistent quality and accessibility at competitive prices across the globe. However, synthetic emulsifiers are under challenge from the increasing preference of consumers for natural, bio-based ingredients and regulatory pressure related to health and environmental issues. Addressing these issues, the producers are innovating in the synthetic segment toward creating products more environmentally friendly and have lesser toxicity, thereby retaining relevance in a constantly shifting market environment.
Food segment to have the highest market share in the emulsifiers market
Food would account for the biggest share of the market for emulsifiers due to the key role these play in the enhancement of quality, texture, and shelf life in the majority of food products. In the formulation of baked goods, confectioneries, dairy products, margarine, dressings, and processed foods, emulsifiers play a huge role, providing uniformity and stability in their formulations. Growing global demand for convenience and processed foods, which arise due to urbanization lifestyle changes, and rising incomes, has increased the requirements for emulsifiers considerably. Further, the health-conscious attitude among consumers has increased demand for low-fat, low-calorie, and clean-label products. Emulsifiers can help manufacturers meet this need because they enhance product functionality and sensory appeal even when fats or calories are reduced. New developments in food emulsifiers, such as bio-based and allergen-free varieties, are increasingly finding application in health-oriented and organic food categories. In addition, the Asia Pacific region is expected to show an increase in the consumption of emulsifier-based food products mainly due to rapid urbanization, an increase in middle-class populations, and changing dietary patterns. Another factor that sustains the dominance of the food segment is the research and development investment by the manufacturers for developing multifunctional emulsifiers tailored specifically for different food applications. As consumer preferences and food trends change, the food segment is likely to continue to be the largest and most dynamic contributor to the emulsifiers market.
Request Sample Pages: <a href="https://www.marketsandmarkets.com/requestsampleNew.asp?id=240653061&utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=emulsifiersmarket" rel="nofollow" target="_blank">https://www.marketsandmarkets.com/requestsampleNew.asp?id=240653061</a>
Europe to be the third largest market during the forecast period.
Europe is expected to be the third-largest region in the emulsifiers market, driven by its mature food and beverage, cosmetics, and pharmaceutical industries. The region’s well-established food processing sector has a consistent demand for emulsifiers, especially in bakery, confectionery, dairy, and convenience food products. Health-conscious consumers in Europe are also driving the market for clean-label and low-fat food products, where emulsifiers play a crucial role in maintaining texture and stability without compromising quality. Another major contributor includes the cosmetics and personal care industry in Europe, driven by the high requirement of quality and sustainability for beauty products from this region. Emulsifiers are used extensively across various skincare, haircare, and makeup formulations concerning improving product texture and stability. The pharmaceutical industry remains expanding in Europe, leveraging emulsifiers for a variety of drug delivery systems. While Europe is a mature market compared to the rapidly growing regions of Asia-Pacific and North America, innovation in bio-based and sustainable emulsifiers is driving growth. The region’s stringent regulations on food and cosmetic ingredients have encouraged the development of natural and environmentally friendly emulsifier solutions, aligning with consumer and regulatory demands. Europe is focusing on sustainability, quality, and advanced formulations. Therefore, despite slower growth compared to emerging markets, Europe ensures its significant presence as the third-largest region in the emulsifiers market.
Request Customization: <a href="https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=240653061&utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=emulsifiersmarket" rel="nofollow" target="_blank">https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=240653061</a>
Key players
The emulsifiers market report comprises key manufacturers such as BASF SE (Germany), Archer Daniels Midland (ADM) (US), Cargill, Incorporated (US), Evonik Industries AG (Germany), Kerry Group plc (Republic of Ireland), Solvay (Belgium), Royal DSM (Netherlands), International Flavors & Fragrances Inc. IFF (US), Corbion (Netherlands), DOW (US), Nouryon (Netherlands), and CLARIANT (Switzerland) among others.
Get access to the latest updates on <a href="https://www.marketsandmarkets.com/ResearchInsight/emulsifier-market.asp?utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=emulsifiersmarket" rel="nofollow" target="_blank">Emulsifiers Companies</a> and <a href="https://www.marketsandmarkets.com/PressReleases/emulsifier.asp?utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=emulsifiersmarket" rel="nofollow" target="_blank">Emulsifiers Market Size</a>
Browse Adjacent Market: <a href="https://www.marketsandmarkets.com/speciality-chemicals-market-research-57.html#utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=category" rel="nofollow" target="_blank">Specialty Chemicals Market</a> Research Reports & Consulting
Related Reports:
<a href="https://www.marketsandmarkets.com/Market-Reports/non-crimp-fabric-market-101091599.html?utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=related-reports" rel="nofollow" target="_blank">Non Crimp Fabric Market</a> – Global Forecast To 2029
<a href="https://www.marketsandmarkets.com/Market-Reports/light-curable-adhesives-market-116182823.html?utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=related-reports" rel="nofollow" target="_blank">Light Curable Adhesives Market</a> – Global Forecast to 2029
<a href="https://www.marketsandmarkets.com/Market-Reports/self-adhesive-tear-tapes-market-43377270.html?utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=related-reports" rel="nofollow" target="_blank">Self-Adhesive Tear Tapes Market</a> – Global Forecast To 2030
<a href="https://www.marketsandmarkets.com/Market-Reports/pvc-adhesive-market-86290998.html?utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=related-reports" rel="nofollow" target="_blank">PVC Adhesive Market</a> – Global Forecast To 2030
<a href="https://www.marketsandmarkets.com/Market-Reports/friction-bonding-adhesive-market-237961768.html?utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=related-reports" rel="nofollow" target="_blank">Friction Bonding Adhesive Market</a> – Global Forecast To 2030
About MarketsandMarkets<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> 
MarketsandMarkets<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit <a href="http://www.marketsandmarkets.com/" rel="nofollow" target="_blank">www.MarketsandMarkets<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" />.com</a> or follow us on <a href="https://twitter.com/marketsmarkets" rel="nofollow" target="_blank">Twitter</a>, <a href="https://www.linkedin.com/company/marketsandmarkets/about/" rel="nofollow" target="_blank">LinkedIn</a> and <a href="https://www.facebook.com/MarketsandMarkets" rel="nofollow" target="_blank">Facebook</a>.
Contact: Mr. Rohan Salgarkar MarketsandMarkets<img src="https://s.w.org/images/core/emoji/15.0.3/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: <a href="mailto:sales@marketsandmarkets.com" rel="nofollow" target="_blank">sales@marketsandmarkets.com</a> Visit Our Website: <a href="https://www.marketsandmarkets.com/" rel="nofollow" target="_blank">https://www.marketsandmarkets.com/</a>
Logo: <a href="https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg" rel="nofollow" target="_blank">https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg</a>
 
<img loading="lazy" decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN93428&sd=2025-01-10" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/emulsifiers-market-worth-8-19-billion-by-2029--exclusive-report-by-marketsandmarkets-302347768.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/emulsifiers-market-worth-8-19-billion-by-2029–exclusive-report-by-marketsandmarkets-302347768.html</a>
 <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN93428&Transmission_Id=202501100645PR_NEWS_EURO_ND__EN93428&DateId=20250110" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.
]]></content:encoded>
</item>
<item>
<title>Diamyd Medical confirms key advances toward Accelerated Approval for Diamyd® following FDA Type C Meeting</title>
<link>https://thenewsthisweek.co.uk/diamyd-medical-confirms-key-advances-toward-accelerated-approval-for-diamyd-following-fda-type-c-meeting-15388/</link>
<dc:creator><![CDATA[PR Newswire]]></dc:creator>
<pubDate>Fri, 10 Jan 2025 11:07:00 +0000</pubDate>
<category><![CDATA[Brand Post]]></category>
<guid isPermaLink="false">https://thenewsthisweek.co.uk/diamyd-medical-confirms-key-advances-toward-accelerated-approval-for-diamyd-following-fda-type-c-meeting-15388/</guid>
<description><![CDATA[STOCKHOLM, Jan. 10, 2025 /PRNewswire/ — Diamyd Medical provides an update following the receipt of final meeting minutes from a positive Type C meeting with the U.S. Food and Drug Administration (FDA) held in December 2024. The meeting focused on refining study protocol and analysis strategies for Diamyd® (rhGAD65/alum) in preparation for Accelerated Approval of the […]]]></description>
<content:encoded><![CDATA[
STOCKHOLM, Jan. 10, 2025 /PRNewswire/ — Diamyd Medical provides an update following the receipt of final meeting minutes from a positive Type C meeting with the U.S. Food and Drug Administration (FDA) held in December 2024. The meeting focused on refining study protocol and analysis strategies for Diamyd® (rhGAD65/alum) in preparation for Accelerated Approval of the antigen-specific immunotherapy targeting Stage 3 Type 1 Diabetes. The final minutes from the Type C meeting confirm alignment on critical development milestones and the statistical plan, setting the stage for an expedited review pathway.
As previously announced on December 13, Diamyd Medical had held a positive in-person meeting with the FDA. Following the meeting, Diamyd Medical has now received the final minutes. The FDA provided affirmative feedback on several pivotal aspects of Diamyd Medical’s development program, including:
Accelerated Approval Pathway: Confirmation that the ongoing DIAGNODE-3 Phase 3 trial aligns with requirements for an Accelerated Approval, leveraging interim efficacy data based on stimulated C-peptide as the primary endpoint from approximately 170 evaluable participants who will complete their 15-month assessments by early 2026.
Safety Dataset and Confirmatory Evidence: Concurrence on the suitability of both the safety dataset and the confirmatory evidence for a potential accelerated approval. The safety dataset includes data from DIAGNODE-3 at filing, along with data from other intralymphatic trials with Diamyd® and the three placebo-controlled trials evaluating subcutaneous injections of Diamyd® from the original meta-analysis published by Hannelius et al. in Diabetologia (2020). Furthermore, concurrence on that DIAGNODE-3 serves as the pivotal trial to demonstrate substantial evidence of effectiveness, supported by DIAGNODE-2 and the aforementioned placebo-controlled trials as confirmatory evidence.
Co-Primary Endpoints: Agreement on simultaneous evaluation of stimulated C-peptide levels and HbA1c as co-primary endpoints at the 24-month final analysis.
Statistical Analysis Plan: Acceptance of the testing strategy for endpoint evaluation, ensuring robust data integrity for both accelerated and full approvals.
The FDA emphasized that the analysis presented in the Trial Outcome Markers Initiative (TOMI) meta-analysis, published by Taylor et al. in Lancet (2023), provides critical insights into the association between C-peptide preservation and clinical outcomes in type 1 diabetes. The FDA agreed that the justification for the required level of C-peptide preservation to support an accelerated approval, including its relationship to a clinically meaningful reduction in HbA1c, could be further discussed at a pre-BLA meeting and included in the Biologics License Application (BLA).
Additionally, the FDA reaffirmed the Orphan Drug Designation for Diamyd® for treating a subset of Type 1 Diabetes patients with residual beta cell function. This designation highlights the therapy’s potential to address significant unmet needs in this well-defined patient population.
About Diamyd Medical
Diamyd Medical develops precision medicine therapies to prevent and treat Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd® is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production. Diamyd® has been granted Orphan Drug Designation in the U.S. as well as Breakthrough Designation and Fast Track Designation by the U.S. FDA for the treatment of Stage 3 Type 1 Diabetes. Diamyd® has also been granted Fast Track Designation for the treatment of Stage 1 and 2 Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes at 60 clinics in eight European countries and in the US. Significant results have previously been shown in a large genetically predefined patient group – in a large-scale meta-analysis as well as in the Company’s prospective European Phase IIb trial, where Diamyd® was administered directly into a superficial lymph node in children and young adults with recently diagnosed Type 1 Diabetes. Injections into a superficial lymph node can be performed in minutes and are intended to optimize the treatment response. A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd®. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB.
Diamyd Medical’s B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.
For further information, please contact: Ulf Hannelius, President and CEO Phone: +46 736 35 42 41 E-mail: <a href="mailto:ulf.hannelius@diamyd.com" rel="nofollow" target="_blank">ulf.hannelius@diamyd.com</a>
This information was brought to you by Cision <a href="https://c212.net/c/link/?t=0&l=en&o=4338022-1&h=526583373&u=http%3A%2F%2Fnews.cision.com%2F&a=http%3A%2F%2Fnews.cision.com" rel="nofollow" target="_blank">http://news.cision.com</a>.
<a href="https://c212.net/c/link/?t=0&l=en&o=4338022-1&h=394913349&u=https%3A%2F%2Fnews.cision.com%2Fdiamyd-medical-ab%2Fr%2Fdiamyd-medical-confirms-key-advances-toward-accelerated-approval-for-diamyd--following-fda-type-c-me%2Cc4089970&a=https%3A%2F%2Fnews.cision.com%2Fdiamyd-medical-ab%2Fr%2Fdiamyd-medical-confirms-key-advances-toward-accelerated-approval-for-diamyd--following-fda-type-c-me%2Cc4089970" rel="nofollow" target="_blank">https://news.cision.com/diamyd-medical-ab/r/diamyd-medical-confirms-key-advances-toward-accelerated-approval-for-diamyd–following-fda-type-c-me,c4089970</a>
The following files are available for download:
<div>
<table border="0" cellpadding="1" cellspacing="0">
<tr>
<td class="prngen1" colspan="1" rowspan="1">
<a class="prnews_a" href="https://c212.net/c/link/?t=0&l=en&o=4338022-1&h=2852326729&u=https%3A%2F%2Fmb.cision.com%2FMain%2F6746%2F4089970%2F3200157.pdf&a=https%3A%2F%2Fmb.cision.com%2FMain%2F6746%2F4089970%2F3200157.pdf" rel="nofollow" target="_blank">https://mb.cision.com/Main/6746/4089970/3200157.pdf</a>
</td>
<td class="prngen1" colspan="1" rowspan="1">
PDF version
</td>
</tr>
</table>
</div>
 
<img loading="lazy" decoding="async" alt="Cision" height="12" src="https://c212.net/c/img/favicon.png?sn=EN93517&sd=2025-01-10" title="Cision" width="12"></img> View original content:<a href="https://www.prnewswire.co.uk/news-releases/diamyd-medical-confirms-key-advances-toward-accelerated-approval-for-diamyd-following-fda-type-c-meeting-302347893.html" id="PRNURL" rel="nofollow" target="_blank">https://www.prnewswire.co.uk/news-releases/diamyd-medical-confirms-key-advances-toward-accelerated-approval-for-diamyd-following-fda-type-c-meeting-302347893.html</a>
 <img decoding="async" alt="" src="https://rt.prnewswire.com/rt.gif?NewsItemId=EN93517&Transmission_Id=202501100607PR_NEWS_EURO_ND__EN93517&DateId=20250110" style="border:0px; width:1px; height:1px;"></img> Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.
]]></content:encoded>
</item>
</channel>
</rss>

If you would like to create a banner that links to this page (i.e. this validation result), do the following:

Download the "valid RSS" banner.
Upload the image to your own server. (This step is important. Please do not link directly to the image on this server.)
Add this HTML to your page (change the image src attribute if necessary):

<a href="http://www.feedvalidator.org/check.cgi?url=https%3A//thenewsthisweek.co.uk/feed/"><img src="valid-rss-rogers.png" alt="[Valid RSS]" title="Validate my RSS feed" /></a>

If you would like to create a text link instead, here is the URL you can use:

http://www.feedvalidator.org/check.cgi?url=https%3A//thenewsthisweek.co.uk/feed/

Home · About · News · Docs · Terms